New drug combo targets rare cancers in early trial
NCT ID NCT00336063
First seen Feb 28, 2026 · Last updated Apr 28, 2026 · Updated 8 times
Summary
This early-phase study tested a combination of two drugs, vorinostat and azacitidine, in 18 adults with nasopharyngeal cancer or nasal NK-T cell lymphoma that had come back or spread. The main goal was to find the safest dose and understand side effects. The study is now complete but not actively recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL KERATINIZING SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese University of Hong Kong-Prince of Wales Hospital
Shatin, Hong Kong
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
National Cancer Center Hospital
Tokyo, 104 0045, Japan
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
National University Hospital Singapore
Singapore, 119074, Singapore
Conditions
Explore the condition pages connected to this study.